How many drugs treat Enterobacter Pneumonia?

Drug Landscape tracks 10 marketed treatments for Enterobacter Pneumonia (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/enterobacter-pneumonia.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Enterobacter Pneumonia — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Enterobacter Pneumonia (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Enterobacter Pneumonia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Maxipime	Cefepime Hydrochloride	Baxter	Cephalosporin	Bacterial cell wall peptidoglycan	1996-01-01
Maxipime	CEFEPIME	Baxter	Cephalosporin Antibacterial		1996-01-01
Cipro	ciprofloxacin	Bayer AG	Fluoroquinolone antibiotic	DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A	1987-10-22
Azactam	AZTREONAM	Bristol-Myers Squibb	Monobactam Antibacterial [EPC]		1986-01-01
Primaxin	IMIPENEM	Merck Sharp & Dohme B.V.	imipenem		1985-01-01
Fortaz	CEFTAZIDIME	Pai Holdings Pharm	ceftazidime		1985-01-01
Primaxin	CILASTATIN	Merck & Co.	Renal Dehydropeptidase Inhibitor	Dipeptidase 1	1985-01-01
Rocephin	ceftriaxone	Generic (originally Roche)	Cephalosporin antibiotic (third-generation)	Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A	1984-12-21
AZLOCILLIN	AZLOCILLIN	Bayer Pharmaceuticals Corp	azlocillin		1982-01-01
Arikayce Kit	AMIKACIN	Bristol-Myers Squibb	Aminoglycoside Antibacterial		1981-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 8 drugs in Enterobacter Pneumonia
Merck & Co. · 3 drugs in Enterobacter Pneumonia
Baxter · 2 drugs in Enterobacter Pneumonia
Bristol-Myers Squibb · 2 drugs in Enterobacter Pneumonia
Pai Holdings Pharm · 2 drugs in Enterobacter Pneumonia
Generic (originally Roche) · 1 drug in Enterobacter Pneumonia
Merck Sharp & Dohme B.V. · 1 drug in Enterobacter Pneumonia
Novartis · 1 drug in Enterobacter Pneumonia
Pfizer · 1 drug in Enterobacter Pneumonia
Poitiers University Hospital · 1 drug in Enterobacter Pneumonia
Sterimax · 1 drug in Enterobacter Pneumonia
Tel-Aviv Sourasky Medical Center · 1 drug in Enterobacter Pneumonia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Enterobacter Pneumonia:

Cite this brief

Drug Landscape (2026). Enterobacter Pneumonia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/enterobacter-pneumonia. Accessed 2026-06-10.

Enterobacter Pneumonia full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing